Please check your internet connection and try again.
# Mega CV
## Overview
Mega CV is a combination medication containing Aspirin and Atorvastatin. Aspirin is an antiplatelet agent, and Atorvastatin is a statin used to lower cholesterol.
## Primary Indications
* **Prevention of cardiovascular events:** In patients with a history of cardiovascular disease or at high risk for cardiovascular events.
* **Lowering lipid levels:** To reduce elevated total-cholesterol, LDL-cholesterol, and triglycerides, and to increase HDL-cholesterol in adults with primary hyperlipidemia or mixed dyslipidemia.
## Adult Dosing
Dosage is individualized based on patient risk factors, lipid profile, and response. The typical starting dose for Atorvastatin is 10 mg once daily, and the typical dose for Aspirin is 75 mg or 81 mg once daily.
* **Mega CV** is available in fixed-dose combinations. The specific strengths should be reviewed for the product available. Common combinations include:
* Atorvastatin 10 mg / Aspirin 75 mg
* Atorvastatin 10 mg / Aspirin 81 mg
* Atorvastatin 20 mg / Aspirin 75 mg
* Atorvastatin 20 mg / Aspirin 81 mg
* Atorvastatin 40 mg / Aspirin 75 mg
* Atorvastatin 40 mg / Aspirin 81 mg
* Atorvastatin 80 mg / Aspirin 75 mg
* Atorvastatin 80 mg / Aspirin 81 mg
* The dose of **Atorvastatin** can range from 10 mg to 80 mg daily.
* The dose of **Aspirin** is typically 75 mg or 81 mg daily.
## Pediatric Dosing
The use of Mega CV in pediatric patients is not established. Atorvastatin alone is indicated for pediatric patients with hyperlipidemia, but specific dosing for combined products like Mega CV is not defined.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required for Atorvastatin or Aspirin in mild to moderate renal impairment. Caution is advised in severe renal impairment.
* **Hepatic Impairment:** Atorvastatin is contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. Dose reduction may be considered in mild hepatic impairment. Aspirin should be used with caution in hepatic impairment.
* **Concomitant Medications:** Adjustments may be necessary based on interactions (see Key Drug Interactions).
## Contraindications
* Hypersensitivity to aspirin, atorvastatin, or any component of the formulation.
* Active liver disease or unexplained persistent elevations of serum transaminases.
* Active bleeding, including gastrointestinal bleeding or intracranial hemorrhage.
* Children with viral infections (due to risk of Reye's syndrome with aspirin).
* Asthma, urticaria, or other allergic-type reactions precipitated by aspirin, NSAIDs, or other medications containing salicylates.
* Use in the third trimester of pregnancy (aspirin component).
## Adverse Effects
* **Common:** Headache, nausea, diarrhea, muscle pain (myalgia), joint pain (arthralgia), upper respiratory tract infection.
* **Serious:**
* **Atorvastatin:** Rhabdomyolysis with acute kidney injury, hepatotoxicity, hyperglycemia, memory impairment, pancreatitis.
* **Aspirin:** Gastrointestinal bleeding, ulceration, tinnitus, hearing loss, bronchospasm, allergic reactions, Reye's syndrome.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Cyclosporine, azole antifungals, macrolide antibiotics, protease inhibitors, and grapefruit juice can increase atorvastatin levels, increasing the risk of myopathy. Rifampin can decrease atorvastatin levels.
* **Other Cholesterol-Lowering Agents:** Fibrates, gemfibrozil, fenofibrate, niacin can increase the risk of myopathy and rhabdomyolysis when used with statins.
* **Anticoagulants and Antiplatelets:** Increased risk of bleeding with warfarin, clopidogrel, heparin, and other antiplatelet agents.
* **Methotrexate:** May increase methotrexate toxicity.
* **Valproic Acid:** May increase the risk of hyperammonemia.
* **NSAIDs:** Increased risk of gastrointestinal bleeding with aspirin and other NSAIDs.
## Monitoring
* **Lipid Panel:** Regularly monitor lipid levels (total cholesterol, LDL-C, HDL-C, triglycerides) to assess efficacy.
* **Liver Function Tests (LFTs):** Baseline and periodically thereafter, especially with dose increases or in patients with risk factors for liver disease.
* **Creatine Kinase (CK):** Monitor if muscle symptoms develop.
* **Renal Function:** Monitor if signs of renal impairment develop.
* **Signs of Bleeding:** Monitor for gastrointestinal bleeding (e.g., melena, hematemesis) and other signs of bleeding.
## Clinical Pearls
* Mega CV offers the convenience of a fixed-dose combination for patients already established on both atorvastatin and aspirin.
* Consider the patient's baseline cardiovascular risk and lipid profile to select the appropriate Mega CV strength.
* Emphasize lifestyle modifications (diet, exercise) in conjunction with medication therapy.
* Patients should be advised to report any new onset of muscle pain, tenderness, or weakness, as well as any signs of bleeding.
* Due to the aspirin component, caution should be exercised in patients with asthma, nasal polyps, or a history of salicylate sensitivity.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Local protocols may dictate specific dosing and monitoring parameters.*
